KeyBanc analyst Donald Hooker raised the firm’s price target on Livongo Health to $105 from $85 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 18%, or $14.05, to $91.68. Most of the “sizeable” preannounced Q2 revenue beat came from higher member enrollment, which should carry over into future periods, Hooker tells investors in a research note. The analyst now models revenue growth of 100% in 2020 and 56% in 2021 for Livongo. In a “bull case scenario,” Hooker sees further upside potential from an “emerging $15B greenfield opportunity” in Medicare.